Switch to:
More From Other Websites
Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze®... Dec 19 2014
Equity markets surge...so many stories – where to begin? Dec 17 2014
Stocks Close Near Session Lows And Down For The Week Dec 12 2014
The rout was on, as major averages post worst weekly loss since 2012 Dec 12 2014
Stocks Down In Afternoon; Caterpillar, Joy Global Hit Dec 12 2014
Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe... Dec 11 2014
Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe... Dec 11 2014
JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 Dec 10 2014
Stock Market Today: Wall Street Drops; Conn's Down 40% Dec 09 2014
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update Dec 09 2014
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update Dec 09 2014
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update Dec 09 2014
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update Dec 09 2014
Top Global Stocks: Jazz, Actavis In IBD's World List Dec 08 2014
Stocks Sink In Late Trading: Tesla, McDonald's Dive Dec 08 2014
Stock Market Today: Indexes Close With Small Losses Dec 04 2014
Jazz Pharmaceuticals (JAZZ) Starts Late-Stage Study on Xyrem Dec 03 2014
Top Funds Gobble Up Tech And Medical Stocks Dec 02 2014
Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic... Dec 02 2014
Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem® (Sodium Oxybate)... Dec 02 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK